Tesamorelin has an FDA-approved HIV lipodystrophy indication, but not for longevity, ordinary weight loss, cognition, bodybuilding, or anti-aging.
Retatrutide is promising in obesity trials, but products sold as retatrutide outside trials have triggered liver-toxicity warnings. Here is how clinic buyers can separate legitimate care from grey-market peptide risk.
The public follistatin and klotho study is a completed, industry-sponsored early-phase trial with 14 participants and no posted results. Here is what that means before paying for treatment.
What the FDA's July meeting did and did not change for BPC-157, TB-500, MOTS-c, Semax, Epitalon and other peptides marketed by longevity clinics.
WLC withdrew its 2026 peptide-clinic ranking because provider flags, marketing sources, dose tables, prices, and a claimed FDA reclassification did not support a safe recommendation.
An HHS announcement prompted reports of a peptide reclassification. Later FDA records show why an announcement, compounding policy, drug approval, and clinical evidence are different questions.
WLC withdrew its 2026 stem-cell clinic ranking because the evidence did not support recommendations, prices, candidate profiles, or maintenance schedules. Here is what patients can verify instead.
